Market closed
Omeros/$OMER
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Omeros
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Ticker
$OMER
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
198
Website
Omeros Metrics
BasicAdvanced
$532M
-
-$2.27
1.48
-
Price and volume
Market cap
$532M
Beta
1.48
52-week high
$13.60
52-week low
$2.61
Average daily volume
492K
Financial strength
Current ratio
2.965
Quick ratio
2.329
Long term debt to equity
-265.152
Total debt to equity
-281.143
Interest coverage (TTM)
-6.07%
Management effectiveness
Return on assets (TTM)
-26.87%
Return on equity (TTM)
220.52%
Valuation
Price to book
-3.45
Price to tangible book (TTM)
-3.45
Price to free cash flow (TTM)
-3.513
Growth
Earnings per share change (TTM)
-813.21%
3-year earnings per share growth (CAGR)
4.46%
What the Analysts think about Omeros
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Omeros stock.
Omeros Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Omeros Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Omeros News
AllArticlesVideos
Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us
Seeking Alpha·10 hours ago
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
Business Wire·5 days ago
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Omeros stock?
Omeros (OMER) has a market cap of $532M as of February 25, 2025.
What is the P/E ratio for Omeros stock?
The price to earnings (P/E) ratio for Omeros (OMER) stock is 0 as of February 25, 2025.
Does Omeros stock pay dividends?
No, Omeros (OMER) stock does not pay dividends to its shareholders as of February 25, 2025.
When is the next Omeros dividend payment date?
Omeros (OMER) stock does not pay dividends to its shareholders.
What is the beta indicator for Omeros?
Omeros (OMER) has a beta rating of 1.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.